[Helicobacter pylori eradication for gastric MALT lymphoma].

Shotaro Nakamura, Takayuki Matsumoto, Takanari Kitazono

研究成果: Contribution to journalReview article査読

1 被引用数 (Scopus)


Clinical features and efficacy of Helicobacter pylori (H. pylori) eradication for patients with gastric MALT lymphoma are reviewed. Gastric MALT lymphoma comprises 1-5% of all gastric malignancies, while 40-50% of primary gastric lymphomas. In approximately 90% of cases, H. pylori infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 60-90% of cases. Predictive factors for resistance to eradication therapy include absence of H. pylori infection, deep invasion in the gastric wall, t(11:18)/API2-MALT1, and etc. Recently a large-scale Japanese multicenter study demonstrated that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent.

ジャーナルUnknown Journal
出版ステータス出版済み - 1 1 2013

All Science Journal Classification (ASJC) codes

  • Medicine(all)

フィンガープリント 「[Helicobacter pylori eradication for gastric MALT lymphoma].」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。